Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7176500 | 1.00 | ANPEP (0.33) | ANPEPERAP2EPHX1GABBR2GABBR1 | |
| SCHEMBL7176498 | 1.00 | ANPEP (0.33) | ANPEPERAP2EPHX1GABBR2GABBR1 | |
| SCHEMBL5528741 | 0.90 | ALDH1A1 (0.34) | ANPEPERAP2EPHX1 | |
| SCHEMBL5537099 | 0.79 | ANPEP (0.37) | ANPEPERAP2GABBR2GABBR1 | |
| SCHEMBL6056283 | 0.79 | ANPEP (0.37) | ANPEPERAP2GABBR2GABBR1 | |
| SCHEMBL6056274 | 0.79 | ANPEP (0.37) | ANPEPERAP2GABBR2GABBR1 | |
| SCHEMBL5394771 | 0.75 | TP53 (0.45) | ANPEPERAP2EPHX1GABBR2GABBR1 | |
| SCHEMBL5394744 | 0.73 | TP53 (0.48) | ANPEPERAP2EPHX1 | |
| SCHEMBL5388081 | 0.73 | TP53 (0.48) | ANPEPERAP2EPHX1 | |
| SCHEMBL5386055 | 0.70 | ANPEP (0.35) | ANPEPERAP2GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161706-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-07-12 | — | — | US | disclosed |
| CN-1635887-A | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | WARNER LAMBERT CO (US) | 2005-07-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161706-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | ANPEP 2033/4885ERAP2 3008/4885EPHX1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.